Search
ALGRX 1207
go.drugbank.com/drugs/DB06482ExperimentalALGRX 1207 entered clinical trials for cutaneous neuropathic pain, such as chemotherapy-induced neuropathy, in 2006. It was being developed by Anesiva, but trials have halted.
HEPES
go.drugbank.com/drugs/DB16872InvestigationalCategories: Compounds used in a research, industrial, or household settingFoslevodopa
go.drugbank.com/drugs/DB16683ApprovedFoslevodopa is under investigation in clinical trial NCT04750226 (Study to Assess Adverse Events and Change in Disease Activity of 24-hour Continuous Subcutaneous Infusion of ABBV-951 in Adult Participants
Zunsemetinib
go.drugbank.com/drugs/DB16502InvestigationalAdditionally, ATI-450 was studied in a terminated trial (NCT05511519) to treat patients with psoriatic arthritis. … ATI-450 was under investigation in clinical trials (NCT05279417 and NCT05216224) for treating patients with rheumatoid arthritis and hidradenitis suppurativa, respectively.
SAR443122
go.drugbank.com/drugs/DB16492InvestigationalSAR443122, was investigated in several clinical trials to evaluate its safety and efficacy. … Additionally, NCT04781816, which was completed with results, focused on patients with cutaneous lupus erythematosus.
Synonyms: 1H-1,2,4-TRIAZOLE-5-CARBOXAMIDE, 3-(PHENYLMETHYL)-N-((3S)-2,3,4,5-TETRAHYDRO-5-METHYL-4-OXOPYRIDO(3,2-B)(1,4)OXAZEPIN-3-YL)-, 3-(PHENYLMETHYL)-N-((3S)-2,3,4,5-TETRAHYDRO-5-METHYL-4-OXOPYRIDO(3,2-B)(1,4)OXAZEPIN-3-YL)-1H-1,2,4-TRIAZOLE-5-CARBOXAMIDEBrivudine
go.drugbank.com/drugs/DB03312ApprovedInvestigationalBrivudine is used in the treatment of herpes zoster. Although not approved in the U.S. or Canada, it is approved in several European countries.
Synonyms: (E)-5-(2-Bromovinyl)-deoxyuridineDilmapimod
go.drugbank.com/drugs/DB12140InvestigationalDilmapimod (SB-681323) is a p38 MAP-kinase inhibitor that has potential uses in inflammatory conditions such as RA (Rheumatoid Arthritis). … Previous p38 MAP-kinase inhibitors have been hindered in development by liver toxicity. Methotrexate (common treatment for RA patients) also has potential liver toxicity.}
XL765
go.drugbank.com/drugs/DB05241InvestigationalXL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR).